Sano Genetics

@sanogenetics

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine

Cambridge, England

sanogenetics.com

Replies Reposts Media

Sano Genetics
@sanogenetics
9h
A negative test result usually feels like an ending. In rare disease research, it can be the start of something else. FDA draft guidance states that natural history data can play a role at every stage of drug development, including as an external control arm. That kind of reuse
1
Sano Genetics
@sanogenetics
Sep 15
AI can cut a drug discovery timeline dramatically, but there's still a lot if can't change. In last week's episode of The Genetics Podcast, Dr. Dave Hallett, Chief Scientific Officer at Recursion, breaks down where AI is genuinely accelerating drug discovery and where the hype
Sano Genetics
@sanogenetics
Sep 14
🧬 The FDA recommends up to 15 years of long-term follow-up for gene therapies that use integrating vectors, up to 15 years for genome editing, and up to five years for AAV vectors, each set by product-specific risk assessment. Follow-up frequently continues after licensure, and
Sano Genetics
@sanogenetics
Sep 11
In the latest episode of The Genetics Podcast, Dr. Danny Miller of the University of Washington and Seattle Children's Hospital makes the case for long-read sequencing, a single test that can capture the kinds of genetic changes usually spread across several separate tests. The
Sano Genetics
@sanogenetics
Sep 10
Rare disease recruitment gets even harder when eligibility depends on genetics or biomarkers. Patients may be extremely rare, geographically dispersed, or still undiagnosed, and by the time enrollment pressure hits, sponsors may already be working with a limited set of options.